Harwood Feffer LLP Announces Investigation of DURECT Corporation

NEW YORK, March 7, 2014 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against DURECT Corporation ("DURECT" or the "Company") (NASDAQ: DRRX) and its board of directors concerning whether the board has breached its fiduciary duties to shareholders or violated the federal securities laws.

On February 12, 2014, the Company disclosed that the FDA had issued a Complete Response Letter for the Company's product candidate, POSIDUR.  The Complete Response Letter means that the FDA will not approve POSIDUR's application for marketing approval in its current form.

If you own DURECT's shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq.
Matthew M. Houston, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
                         (212) 935-7400
Email:  bsachsmichaels@hfesq.com
Website:   http://www.hfesq.com

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. © 2014 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Photo - http://photos.prnewswire.com/prnh/20120215/MM54604LOGO

SOURCE Harwood Feffer LLP